![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MSN |
Gene summary for MSN |
![]() |
Gene information | Species | Human | Gene symbol | MSN | Gene ID | 4478 |
Gene name | moesin | |
Gene Alias | HEL70 | |
Cytomap | Xq12 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P26038 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4478 | MSN | LZE4T | Human | Esophagus | ESCC | 6.82e-26 | 1.36e+00 | 0.0811 |
4478 | MSN | LZE7T | Human | Esophagus | ESCC | 1.14e-04 | 9.29e-01 | 0.0667 |
4478 | MSN | LZE8T | Human | Esophagus | ESCC | 2.22e-05 | 4.44e-01 | 0.067 |
4478 | MSN | LZE6T | Human | Esophagus | ESCC | 2.08e-14 | 1.06e+00 | 0.0845 |
4478 | MSN | P2T-E | Human | Esophagus | ESCC | 1.12e-49 | 9.76e-01 | 0.1177 |
4478 | MSN | P4T-E | Human | Esophagus | ESCC | 1.34e-18 | 3.39e-01 | 0.1323 |
4478 | MSN | P5T-E | Human | Esophagus | ESCC | 5.63e-32 | 8.52e-01 | 0.1327 |
4478 | MSN | P8T-E | Human | Esophagus | ESCC | 1.09e-12 | 2.90e-01 | 0.0889 |
4478 | MSN | P9T-E | Human | Esophagus | ESCC | 3.24e-20 | 7.54e-01 | 0.1131 |
4478 | MSN | P10T-E | Human | Esophagus | ESCC | 1.00e-15 | 4.57e-01 | 0.116 |
4478 | MSN | P11T-E | Human | Esophagus | ESCC | 4.71e-22 | 1.38e+00 | 0.1426 |
4478 | MSN | P12T-E | Human | Esophagus | ESCC | 6.60e-05 | -2.15e-02 | 0.1122 |
4478 | MSN | P15T-E | Human | Esophagus | ESCC | 1.32e-16 | 7.57e-01 | 0.1149 |
4478 | MSN | P16T-E | Human | Esophagus | ESCC | 3.40e-31 | 5.91e-01 | 0.1153 |
4478 | MSN | P17T-E | Human | Esophagus | ESCC | 1.52e-19 | 1.30e+00 | 0.1278 |
4478 | MSN | P19T-E | Human | Esophagus | ESCC | 1.40e-13 | 1.88e+00 | 0.1662 |
4478 | MSN | P20T-E | Human | Esophagus | ESCC | 1.87e-29 | 9.82e-01 | 0.1124 |
4478 | MSN | P21T-E | Human | Esophagus | ESCC | 1.48e-56 | 1.39e+00 | 0.1617 |
4478 | MSN | P22T-E | Human | Esophagus | ESCC | 1.49e-42 | 9.32e-01 | 0.1236 |
4478 | MSN | P23T-E | Human | Esophagus | ESCC | 6.26e-11 | 5.54e-01 | 0.108 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000188512 | Liver | HCC | endothelial cell development | 37/7958 | 64/18723 | 9.63e-03 | 3.63e-02 | 37 |
GO:00098968 | Lung | IAC | positive regulation of catabolic process | 114/2061 | 492/18723 | 4.93e-15 | 1.25e-11 | 114 |
GO:00421768 | Lung | IAC | regulation of protein catabolic process | 97/2061 | 391/18723 | 6.32e-15 | 1.25e-11 | 97 |
GO:00313318 | Lung | IAC | positive regulation of cellular catabolic process | 98/2061 | 427/18723 | 7.79e-13 | 9.25e-10 | 98 |
GO:00071637 | Lung | IAC | establishment or maintenance of cell polarity | 61/2061 | 218/18723 | 3.10e-12 | 3.07e-09 | 61 |
GO:00300107 | Lung | IAC | establishment of cell polarity | 46/2061 | 143/18723 | 7.70e-12 | 4.27e-09 | 46 |
GO:00457328 | Lung | IAC | positive regulation of protein catabolic process | 61/2061 | 231/18723 | 4.44e-11 | 1.39e-08 | 61 |
GO:00226048 | Lung | IAC | regulation of cell morphogenesis | 74/2061 | 309/18723 | 6.31e-11 | 1.70e-08 | 74 |
GO:19033628 | Lung | IAC | regulation of cellular protein catabolic process | 63/2061 | 255/18723 | 4.30e-10 | 9.45e-08 | 63 |
GO:00020648 | Lung | IAC | epithelial cell development | 52/2061 | 220/18723 | 6.75e-08 | 6.91e-06 | 52 |
GO:19033648 | Lung | IAC | positive regulation of cellular protein catabolic process | 40/2061 | 155/18723 | 1.84e-07 | 1.56e-05 | 40 |
GO:00083607 | Lung | IAC | regulation of cell shape | 37/2061 | 154/18723 | 3.35e-06 | 1.42e-04 | 37 |
GO:00610287 | Lung | IAC | establishment of endothelial barrier | 16/2061 | 46/18723 | 1.72e-05 | 4.88e-04 | 16 |
GO:00164826 | Lung | IAC | cytosolic transport | 37/2061 | 168/18723 | 2.74e-05 | 7.26e-04 | 37 |
GO:00323867 | Lung | IAC | regulation of intracellular transport | 60/2061 | 337/18723 | 1.16e-04 | 2.22e-03 | 60 |
GO:00018856 | Lung | IAC | endothelial cell development | 18/2061 | 64/18723 | 1.30e-04 | 2.44e-03 | 18 |
GO:19016548 | Lung | IAC | response to ketone | 39/2061 | 194/18723 | 1.40e-04 | 2.60e-03 | 39 |
GO:19021152 | Lung | IAC | regulation of organelle assembly | 37/2061 | 186/18723 | 2.55e-04 | 4.26e-03 | 37 |
GO:00325357 | Lung | IAC | regulation of cellular component size | 65/2061 | 383/18723 | 2.56e-04 | 4.26e-03 | 65 |
GO:00901626 | Lung | IAC | establishment of epithelial cell polarity | 11/2061 | 31/18723 | 2.91e-04 | 4.72e-03 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0453022 | Liver | Cirrhotic | Tight junction | 82/2530 | 169/8465 | 2.14e-07 | 2.85e-06 | 1.76e-06 | 82 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0520510 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0467022 | Liver | Cirrhotic | Leukocyte transendothelial migration | 49/2530 | 114/8465 | 1.92e-03 | 8.55e-03 | 5.27e-03 | 49 |
hsa0453032 | Liver | Cirrhotic | Tight junction | 82/2530 | 169/8465 | 2.14e-07 | 2.85e-06 | 1.76e-06 | 82 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0520511 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0467032 | Liver | Cirrhotic | Leukocyte transendothelial migration | 49/2530 | 114/8465 | 1.92e-03 | 8.55e-03 | 5.27e-03 | 49 |
hsa0453042 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
hsa0467042 | Liver | HCC | Leukocyte transendothelial migration | 68/4020 | 114/8465 | 5.79e-03 | 1.64e-02 | 9.15e-03 | 68 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MSN | SNV | Missense_Mutation | c.1189N>A | p.Glu397Lys | p.E397K | P26038 | protein_coding | tolerated(0.32) | possibly_damaging(0.61) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
MSN | SNV | Missense_Mutation | c.1678C>T | p.Arg560Cys | p.R560C | P26038 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
MSN | SNV | Missense_Mutation | c.1507N>T | p.Arg503Cys | p.R503C | P26038 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MSN | SNV | Missense_Mutation | c.855N>A | p.Met285Ile | p.M285I | P26038 | protein_coding | tolerated(0.23) | benign(0.029) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MSN | SNV | Missense_Mutation | rs753856958 | c.659N>G | p.Val220Gly | p.V220G | P26038 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MSN | SNV | Missense_Mutation | rs770945316 | c.299G>A | p.Arg100His | p.R100H | P26038 | protein_coding | tolerated(0.58) | benign(0.068) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
MSN | SNV | Missense_Mutation | novel | c.1034A>G | p.Glu345Gly | p.E345G | P26038 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
MSN | insertion | In_Frame_Ins | novel | c.342_343insCTCACCTTACCCTTACCCTCCACTTGCATCCTTCTCCCAAAAAAC | p.Asp114_Ile115insLeuThrLeuProLeuProSerThrCysIleLeuLeuProLysAsn | p.D114_I115insLTLPLPSTCILLPKN | P26038 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
MSN | SNV | Missense_Mutation | novel | c.322N>A | p.Glu108Lys | p.E108K | P26038 | protein_coding | tolerated(0.09) | possibly_damaging(0.47) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MSN | SNV | Missense_Mutation | rs778459733 | c.835N>T | p.Arg279Trp | p.R279W | P26038 | protein_coding | deleterious(0.03) | possibly_damaging(0.598) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |